Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Julphar
Fish and Richardson
Harvard Business School
Cerilliant
Deloitte
McKinsey
Covington
Federal Trade Commission
Chinese Patent Office

Generated: January 19, 2018

DrugPatentWatch Database Preview

KYNAMRO Drug Profile

« Back to Dashboard

Summary for KYNAMRO
International Patents:577
US Patents:6
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Drug Prices:see details
DailyMed Link:KYNAMRO at DailyMed
Drug patent expirations by year for KYNAMRO

US Patents and Regulatory Information for KYNAMRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for KYNAMRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 ➤ Subscribe ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 ➤ Subscribe ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 ➤ Subscribe ➤ Subscribe
Kastle Theraps Llc KYNAMRO mipomersen sodium SOLUTION;SUBCUTANEOUS 203568-001 Jan 29, 2013 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for KYNAMRO

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,803,930 Antisense modulation of apolipoprotein B-expression ➤ Subscribe
5,760,202 Process for the synthesis of 2'-O-substituted pyrimidines ➤ Subscribe
RE44760 Antisense modulation of apolipoprotein B-expression ➤ Subscribe
5,861,493 Process for the synthesis of 2'-O-substituted pyrimidines ➤ Subscribe
7,888,324 Antisense modulation of apolipoprotein B expression ➤ Subscribe
6,642,367 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom ➤ Subscribe
6,222,025 Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom ➤ Subscribe
8,735,364 Antisense modulation of apolipoprotein B expression ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for KYNAMRO

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Covington
AstraZeneca
McKinsey
Cipla
UBS
Fish and Richardson
Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot